Advances In Pediatric Oncology Treatments Using Personalized Immunotherapy And Precision Medicine

Abstract

Background: Pediatric cancers continue to be among the major causes of morbidity and mortality in children globally. Chemotherapy, radiation therapy and surgery are traditional treatment modalities that improve survival but are often associated with significant adverse effects and heterogeneous treatment outcomes. Personalized immunotherapy and precision medicine have transformed pediatric oncology by providing targeted and personalized treatment approaches based on genetic, molecular, and immunological characteristics. Objective: To review the recent advances of personalized immunotherapy and precision medicine to improve treatment outcomes of pediatric oncology patients.  Methodology: An extensive review of current therapeutic approaches including chimeric antigen receptor T-cell (CAR-T) therapy, immune checkpoint inhibitors, targeted molecular therapies, genomic profiling and paradigms of precision medicine was conducted based on clinical trials and cancer databases. Treatment efficacy, response rates, progression free survival and clinical outcomes were evaluated.  Findings: The analysis showed that personalized immunotherapy led to a treatment response rate of 82%–94% in selected cases of pediatric cancers. CAR-T cell therapy yielded remission rates exceeding 90% in relapsed pediatricleukemia patients, while precision medicine-guided treatments enhanced progression-free survival by approximately 38% and decreased treatment-related complications by around 30%.  Conclusion: Personalized immunotherapy and precision medicine significantly enhance the efficacy of treatment, survival and quality of care in pediatric oncology. The continued integration of genomic profiling with targeted therapies is expected to further precision cancer treatment and improve long-term outcomes for children with cancer.